Monogenetic Disease Therapy Market Growth Through 2030 Creates New Strategic Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Monogenetic Disease Therapy Market Revenue Outlook: What CAGR Is Expected Through 2030?
The monogenetic disease therapy market size has seen robust expansion in recent years. It is anticipated to increase from $28.3 billion in 2025 to $31.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. The growth observed in prior periods can be attributed to developments in human genome research, the early stages of gene therapy trials, an escalation in rare disease diagnoses, the availability of orphan drug incentives, and progress in viral vectors.
The monogenetic disease therapy market is poised for significant expansion in the coming years. Its size is expected to reach $45.58 billion by 2030, progressing at a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period is attributed to several factors, including advancements in gene editing platforms, an increased pipeline for rare disease treatments, higher rates of genetic screening, greater funding for personalized therapies, and more extensive regulatory approvals. Furthermore, major trends anticipated in this period comprise single gene targeted therapies, gene replacement treatment programs, RNA-based genetic treatments, gene correction for rare diseases, and precision genetic drug design.
Download A Free Sample Report For Comprehensive Market Insights:
#Monogenetic Disease Therapy Market Growth Drivers And Industry Catalysts
The increasing acceptance of precision and personalized medicine is anticipated to drive the future growth of the monogenetic disease therapy market. This medical approach involves tailoring disease prevention, diagnosis, and treatment according to an individual’s unique genetic, molecular, or lifestyle characteristics to maximize therapeutic efficacy and minimize adverse effects. The rise of precision and personalized medicine is largely due to healthcare providers and patients seeking individualized treatments that optimize therapeutic efficacy, reduce unwanted side effects, and consider specific genetic, molecular, or lifestyle factors. Monogenetic disease therapy supports precision and personalized medicine by specifically targeting a patient’s genetic mutation, thereby enabling highly customized and effective treatments. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a notable increase from six in 2022. Therefore, the growing adoption of precision and personalized medicine is acting as a key driver for the expansion of the monogenetic disease therapy market.
Monogenetic Disease Therapy Market Segments: Where Are The Largest Growth Opportunities?
The monogenetic disease therapy market covered in this report is segmented –
1) By Therapy Type: Pharmacological; Surgical; Blood Transfusion; Gene Therapies; Other Therapy Types
2) By Inheritance Pattern: Autosomal; Chromosomal
3) By Application: Cystic Fibrosis; Sickle Cell Anemia; Phenylketonuria; Other Applications
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users
Subsegments:
1) By Pharmacological: Small Molecule Drugs; Enzyme Replacement Therapies; Protein Replacement Therapies; Immunomodulatory Drugs; Targeted Molecular Therapies
2) By Surgical: Organ Transplant Procedures; Tissue Repair Surgeries; Gene Editing Assisted Surgeries; Minimally Invasive Surgeries; Corrective Surgical Interventions
3) By Blood Transfusion: Red Blood Cell Transfusions; Platelet Transfusions; Plasma Transfusions; Stem Cell Infusions; Autologous Blood Transfusions
4) By Gene Therapies: Ex Vivo Gene Therapy; In Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Vector Gene Therapy; Genome Editing Based Therapy
5) By Other Therapy Types: Cell Based Therapies; RNA Based Therapies; Protein Based Therapies; Combination Therapies; Experimental Therapies
#Monogenetic Disease Therapy Market Trends Influencing Long-Term Demand
Major companies within the monogenetic disease therapy market are concentrating on developing innovative gene therapies, including Duchenne muscular dystrophy (DMD)–targeted protocols, to slow disease progression and enhance long-term patient outcomes. Duchenne muscular dystrophy–targeted protocols are defined as structured clinical or therapeutic guidelines specifically crafted to diagnose, monitor, and manage patients afflicted with Duchenne muscular dystrophy, with an emphasis on mitigating disease progression, improving muscle function, and addressing associated complications. For instance, in January 2026, Sarepta Therapeutics Inc, a US-based biopharmaceutical company, launched Elevidys for ambulatory patients aged four and older with DMD. This treatment showed up to a 73% reduction in the rate of functional decline over three years when compared with an external control group, highlighting the importance of early intervention in altering the disease course and improving the quality of life.
Monogenetic Disease Therapy Market Major Participants And Competitive Dynamics
Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.
Access The Complete Monogenetic Disease Therapy Market Report:
Monogenetic Disease Therapy Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the monogenetic disease therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monogenetic disease therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
